Elahere is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Elahere is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameElahere
Authorized genericmirvetuximab soravtansine
Regular genericmirvetuximab soravtansine
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Elahere?
The original
–
–

Brand nameThe maker’s card

ELAHERE Support Services (ESS) Co-pay Assistance Program

Savings card from AbbVie (ImmunoGen)

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

The card takes up to $25,000 a year off your co-pay.

Sign up on elahere.com 

Or call 1-833-352-4373.

In the maker’s words

“If you have commercial insurance and meet eligibility criteria, you may pay as little as $0 per dose for ELAHERE with the Co-pay Assistance Program.”

From the maker’s offer on elahere.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Elahere itself, from the same company, sold without the brand name, and usually for less. For now Elahere is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Elahere is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

Source: the FDA label for Elahere (ImmunoGen, Inc.), July 14, 2025. Full label on DailyMed 

Good to know